NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.

Paul B MullanVictoria BinghamPaula HaddockGareth W IrwinElaine KayStephen McQuaidNiamh E Buckley

Published in: BMC cancer (2019)

We have identified a novel biomarker, NUP98, that can predict response to anthracycline based chemotherapy in TNBC. The ability to prospectively identify patients who are less likely to respond to SoC chemotherapy is a vital step in improving the overall survival of these patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
locally advanced
peritoneal dialysis
squamous cell carcinoma
radiation therapy
patient reported outcomes